^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
Labcorp® Plasma Detect™

Company:
LabCorp
Type:
Laboratory Developed Test
Related tests:
Evidence

News

7ms
Labcorp Expands Collaboration with Ultima Genomics to Advance Whole Genome Sequencing Applications and Oncology Testing Capabilities (PRNewswire)
"Labcorp...announced an expanded collaboration with Ultima Genomics to utilize its UG 100TM sequencing solution and ppmSeq technology to explore new whole genome sequencing (WGS) clinical applications, including molecular residual disease (MRD) in patients with early-stage solid tumor cancers."
Licensing / partnership
|
Labcorp® Plasma Detect™
11ms
Labcorp launches Labcorp® Plasma Detect™ extending leadership into molecular residual disease (MRD) clinical research (LabCorp Press Release)
"Labcorp...announced today the launch of Labcorp® Plasma Detect™, the first clinically validated, tumor-informed, whole-genome sequencing circulating tumor DNA (ctDNA) molecular residual disease (MRD) solution in early stage colon cancer to identify patients at increased risk of recurrence after surgery or adjuvant chemotherapy (ACT). This solution, which is designed for research use but also suitable for clinical applications, can be applied across solid tumors with a scalable and standardized approach to facilitate faster turnaround times while maintaining high analytical performance."
Launch
|
Labcorp® Plasma Detect™